Arpida and Evolva of Switzerland to merge
Arpida Ltd and Evolva SA have announced plans to merge to create a larger, publicly-listed biotechnology company with a pipeline of drug candidates as well as revenue-generating discovery partnerships.
News
Osiris says stem-cell trials do not meet endpoint
Osiris Therapeutics Inc said that preliminary results from two Phase 3 trials of its stem cell treatment for acute graft-versus-host disease (GvHD) did not reach their primary endpoints.
Roche appoints four senior managers to its executive committee
- The Roche Group has appointed four new managers to its executive committee following the retirement of two managers and the company’s assumption of full control of its US biotechnology affiliate, Genentech Inc.
Scientists identify three genes that are risks for Alzheimer’s disease
Scientists from the UK and France have identified three genes that appear to increase a person’s chances of developing Alzheimer’s disease, the most common cause of dementia.
ProFibrix raises €8 million in Series B round
ProFibrix BV of the Netherlands has raised €8 million in a Series B round enabling it to carry forward plans to seek FDA authorisation for a combined Phase 2/3 trial in the US of its candidate tissue sealant for use in surgery or trauma injury, Fibrocaps.
Elan responds to US court ruling on J&J collaboration
Elan Corporation Plc said that it will work quickly to resolve objections by a US court to its proposed strategic alliance with Johnson & Johnson that would recapitalise the company and give it the resources to commercialise its pipeline.
Researchers discover two broadly neutralising antibodies against HIV
Researchers from industry and two non-profit organisations have reported the discovery of two new broadly neutralising antibodies against the human immunodeficiency virus (HIV), thus advancing the goal of developing an AIDS vaccine.
Bid to take Celsis International private becomes unconditional
An investor in Celsis International Plc is on the verge of success in acquiring the drug toxicity detection company whose shares are listed on the London Stock Exchange. The investor is North Atlantic Value LLP (NAVLLP), part of the JO Hambro Capital Management Group.
Shire says FDA approves attention-deficit disorder treatment
Shire Plc said that it has received approval from the US Food and Drug Administration to market its treatment for children and adolescents with attention-deficit, hyperactivity disorder (ADHD), strengthening its franchise in this area.
Algeta to receive $61 million upfront for cancer drug
Algeta ASA is to receive $61 million upfront from Bayer Schering Pharma AG in a deal worth up to $800 million to develop and commercialise a radiopharmaceutical for bone metastases in patients with hormone-refractory prostate cancer.